v_diretrizes_brasileira_hipertensao_arterial_2006
50 pág.

v_diretrizes_brasileira_hipertensao_arterial_2006

Disciplina:Anatomia Humana19.405 materiais822.505 seguidores
Pré-visualização32 páginas
B, Lanke J, Schersten B, Wester PO, Hedner T, de
Faire U�� Randomized trial of old and new antihypertensive dr�gs in elderly patients�� cardio�
vasc�lar mortality and morbidity�� The Swedish Trial in Old Patients with Hypertension�2 st�dy��
Lancet ������34����2�–33��

��0�� Dahlof B, Devere�x RB, Kjeldsen SE, J�li�s S, Beevers G, de Faire U, Fyhrq�ist F, Ibsen H,
Kristiansson K, Lederballe�Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel
H�� Cardiovasc�lar morbidity and mortality in the losartan intervention or endpoint red�ction in
hypertension st�dy �LIFE��� a randomized trial against atenolol�� Lancet 2002,3�������–�003��

����� Lindholm LH, Ibsen H, Dahlof B, Devere�x RB, Beevers G, de Faire U, Fyhrq�ist F, J�li�s S,
Kjeldsen SE, Kristiansson K, Lederballe�Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel
H, A�r�p P, Edelman J, Snapinn S�� Cardiovasc�lar morbidity and mortality in patients with
diabetes in the Losartan Intervention For Endpoint red�ction in hypertension st�dy �LIFE��� a
randomized trial against atenolol�� Lancet 2002��3�����004–�0��

��2�� Stassen JÁ, Fagard R, Thijs L�� Randomized do�ble�blind comparison of placebo and active
treatment for older patients with isolated systolic hypertension�� The Systolic hypertension in
E�rope �SYST–EUR��� Lancet ���7��3�0��7�7–��4��

��3�� Brown MJ, Palmer CR, Castaigne A, de Lee�w PW, Mancia G, Rosenthal T, R�ilope LM��
Morbidity and mortality in patients randomized to do�ble�blind treatment with long�acting
calci�m�channel blocker or di�retic in the International Nifedipine GITS st�dy�� Intervention as
a Goal in Hypertension Treatment �INSIGHT��� Lancet 2000��3�����3����–72��

��4�� Hansson L, Hedner T, L�nd�Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de
Faire U, Dahlof B, Karlberg BE�� Randomized trial of effects of calci�m antagonists compared
with di�retics and alpha�blockers on cardiovasc�lar morbidity and mortality in hypertension��
the Nordic Diltiazen �NORDIL� st�dy�� Lancet 2000��3�����3��–�����

46

����� Sykowsky PA, D’Agostino RB, Belanger AJ, Kannel WB�� Sec�lar Trends in Long Term S�s�
tained Hypertension, Long Term Treatment and Cardiovasc�lar Morbidity�� The Framingham
Heart St�dy ���0 to ���0�� Circ�lation ��������3�����7–703��

������ UK Prospective Diabetes St�dy Gro�p�� Tight blood press�re control and the risk of
macrovasc�lar and microvasc�lar complications in type diabetes�� UKPDS 38�� BMJ
���8��3�7��703–�3��

��7�� Hansson L, Zanchetti A, Carr�thers SG, Dahlof B, Elmfeldt D, J�li�s S, Menard J, Rahn KH,
Wedel H, Westerling S�� Effects of intensive blood�press�re lowering and low�dose aspirin
in patients with hypertension�� principal res�lts of the Hypertension Optimal Treatment
�HOT� randomized trial�� Lancet ���8��3�����7��–��2��

��8�� Lewis EJ, H�nsicker LG, Clarke WR�� Renoprotective effect of the angiotensin receptor
antagonist irbesartan in patients with nephropathy d�e to type 2 diabetes�� N Eng J Med
200���34���8��–��0��

����� Brenner BM, Cooper ME, Zee�w D�� Effects of losartan on renal and cardiovasc�lar o�tco�
mes in patients with type 2 diabetes and nephropathy N Engl J Med 200���34���8���–���

���0�� Peterson JC, Adler S, B�rkart JM, Greene T, Hebert LA, H�nsicker LG, King AJ, Klahr S, Mas�
sry SG, Seifter JL�� Blood press�re control, protein�ria, and the progression of renal disease��
The modification of Diet in Renal Disease St�dy �MDRD� Ann Intern Med �������23��7�4–��2��

������ Kr�mholz HM, Parent EM, T� N, Vaccarino V, Wang Y, Radford MJ, Hennen J�� Readmission
after hospitalization for congestive heart fail�re among Medicare beneficiares�� Arch Intern
Med ���7����7�������–�04��

���2�� D� X, Cr�ickshank K, McNamee R, Saraee M, So�rb�tts J, S�mmers A, Roberts N, Walton
E, Holmes S�� Case�Control of stroke and q�ality of hypertension control in north west
England�� BMJ ���7��34���272–����

���3�� T�rnb�ll F, Neal B, Algert C, Chalmers J, Chapman N, C�tler J, Woodward M, MacMahon
S�� Blood Press�re Lowering Treatment Trialists’ Collaboration�� Effects of different blood
press�re�lowering regimens on major cardiovasc�lar events in individ�als with and witho�t
diabetes mellit�s�� res�lts of prospectively designed overviews of randomized trials�� Arch
Intern Med 200����������4�0����

���4�� Calberg B ,Samy�elson O, Lindholm LH�� Atenolol in hypertension�� is it a wise choice?
Lancet 2004��3��4�����84�8���

165. Lindholm LH, Calberg B, Samyuelson O. Should β blocker remain a first choice in the
treatment of primary hypertension? A meta�analysis�� Lancet 200���3��������4���3��

������� Dahlof B, Sever PS, Po�lter NR, Wedel H, Beevers DG, Ca�lfield M, Collins R, Kjeldsen
SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J�� ASCOT
Investigators�� Prevention of cardiovasc�lar events with an antihypertensive regimen of
amlodipine adding perindopril as req�ired vers�s atenolol adding bendrofl�methiazide as
req�ired, in the Anglo�Scandinavian Cardiac O�tcomes Trial�Blood Press�re Lowering Arm
�ASCOT�BPLA��� a m�lticentre randomised controlled trial�� Lancet 200���3������8����0����

���7�� The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Reserach Gro�p�� Major
cardiovasc�lar events in hypertensive patients randomized to doxazosin vs chlorthalidone��
The Antihypertensive and Lipid� LoweringTreatment to prevent Heart Attack Trial �AL�
LHAT��� JAMA 2000��283������7–7���

���8�� Pahor M, Psaty BM, Alderman MH et al�� Health o�tcomes associated with calci�m an�
tagonists compared with other first�line antihypertensive therapies�� a meta�analyses of
randomized controlled trials�� Lancet 2000��3�������4�–�4��

������ J�li�s S, Kjeldsen SE, Weber M, Br�nner HR, Ekman S, Hansson L, H�a T, Laragh J, McIn�
nes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A�� VALUE trial gro�p�� O�tcomes in
hypertensive patients at high cardiovasc�lar risk treated with regimens based on valsartan
or amlodipine�� the VALUE randomised trial�� Lancet 2004��3��3��42�����2022�3���

�70�� L�bsen J, Wagener G, Kirwan BA, de Bro�wer S, Poole�Wilson PA�� ACTION �A Coronary di�
sease Trial Investigating O�tcome with Nifedipine GITS� investigators�� Effect of long�acting
nifedipine on mortality and cardiovasc�lar morbidity in patients with symptomatic stable
angina and hypertension�� the ACTION trial�� J Hypertens 200���23�3�����4��8��

�7��� Sever PS, Dahlof B, Po�lter NP, Wedel H�� Anglo�Scandinavian Cardiac O�tcomes Trial�� Lipid
Lowering Arm �ASCOT LLA� revisited�� interaction of antihypertensive and lipid lowering
therapy�� Circ�lation 200�����2�S�ppl II����34��34��

�72�� Mason PR�� A rationale for combination therapy in risk factor management�� a mechanistic
perspective�� Amer J Med 200�����8��2A�,�4S����S��

�73�� Flather MD, Y�s�f S, Kober L, Pfeffer M, Hall A, M�rray G, Torp�Pedersen C, Ball S, Pog�e
J, Moye L, Bra�nwald E�� Long term ACE�inhibitor therapy in patients with heart fail�re or
left ventric�lar dysf�nction�� a systematic overview of data from individ�al patients�� Lancet
2000��3������7�–8���

�74�� Garg R, Y�ss�f S�� Colaborative Gro�p on ACE�inhibitor Trials�� Overview of randomized trials
of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with
heart fail�re�� JAMA ������273���4�0–����

�7��� Lewis EJ, H�nsicker LG, Bain RP, Rohde RD�� The effect of angiotensin�converting�enzyme
inhibition on diabetic nephropathy�� The Collaborative St�dy Gro�p�� N Engl J Med ���3��
32����4���–���2��

�7���� Gansevoort RT, Sl�iter WJ, Hemmelder MH, de Zee�w D, de Jong PE�� Antiprotein�ric effect
of blood�press�re�lowering agents�� a meta�analysis of comparative trials�� Nephrol Dial Trans�
plant �������0������3–74��

�77�� Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Z�cchelli
P�� Effect of the angiotensin�converting�enzyme